New York State Common Retirement Fund Has $86.03 Million Stock Holdings in Becton, Dickinson and Company (NYSE:BDX)

New York State Common Retirement Fund reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 7.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 356,829 shares of the medical instruments supplier’s stock after selling 27,000 shares during the period. New York State Common Retirement Fund owned about 0.12% of Becton, Dickinson and Company worth $86,031,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the business. Jennison Associates LLC increased its holdings in shares of Becton, Dickinson and Company by 4.9% during the 1st quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock worth $99,562,000 after acquiring an additional 18,786 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Becton, Dickinson and Company by 9.2% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,422 shares of the medical instruments supplier’s stock valued at $14,481,000 after purchasing an additional 5,006 shares during the last quarter. Axxcess Wealth Management LLC raised its position in shares of Becton, Dickinson and Company by 30.2% in the first quarter. Axxcess Wealth Management LLC now owns 11,051 shares of the medical instruments supplier’s stock valued at $2,735,000 after purchasing an additional 2,565 shares during the period. SG Americas Securities LLC lifted its stake in shares of Becton, Dickinson and Company by 206.5% during the 1st quarter. SG Americas Securities LLC now owns 46,328 shares of the medical instruments supplier’s stock worth $11,464,000 after buying an additional 31,215 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. boosted its holdings in shares of Becton, Dickinson and Company by 24.0% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 32,175 shares of the medical instruments supplier’s stock worth $7,962,000 after buying an additional 6,220 shares during the period. Institutional investors and hedge funds own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on BDX. Evercore ISI raised their price objective on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com raised Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Citigroup raised Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and upped their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Stifel Nicolaus lifted their target price on Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Finally, Raymond James decreased their price target on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a research note on Friday, August 2nd. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $282.63.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $235.24 on Friday. The firm has a market capitalization of $67.99 billion, a P/E ratio of 48.40, a P/E/G ratio of 1.77 and a beta of 0.42. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $259.92. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.85 and a quick ratio of 1.36. The company’s 50 day moving average price is $237.56 and its two-hundred day moving average price is $235.05.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a return on equity of 14.49% and a net margin of 7.13%. Becton, Dickinson and Company’s revenue for the quarter was up 2.3% compared to the same quarter last year. During the same period last year, the company earned $2.96 EPS. On average, equities analysts forecast that Becton, Dickinson and Company will post 13.11 earnings per share for the current fiscal year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.